On February 18, 2024, Shenzhen Mindray Biomedical Electronics Co., Ltd. officially released the "Announcement on the Action Plan for Double Improvement of Quality and Return". This action plan is not only a positive response to the requirements of the Politburo meeting and the National Standing Committee on activating the capital market and boosting investor confidence, but also the in-depth practice of the company's "investor-oriented" development concept. The launch of this plan aims to fully safeguard the interests of all shareholders of the company and help the stable and healthy development of the capital market.
As a leading company in the field of medical devices, Mindray has more than 30 years of development history and more than 20 years of overseas layout, which has enabled it to have the most comprehensive product line in the industry, with products covering more than 190 countries and regions around the world. The company's core products such as monitors, anesthesia machines, and ventilators rank among the best in the global market share, and compete fiercely with international first-line equipment companies.
In order to continue to strengthen its R&D strength and expand the market at home and abroad, the company focuses on three major business areas: life information and support, in vitro diagnostics and medical imaging. At the same time, Mindray is actively looking for excellent M&A targets on a global scale to achieve internal and external synergy and common development. In 2023, the company successfully acquired a 75% stake in Diasys, a well-known German IVD brand. Entering 2024, Mindray Medical will make another move, planning to use 66500 million yuan of its own funds to acquire the control of Huitai Medical, a medical device company listed on the Science and Technology Innovation Board, to further improve the layout of the cardiovascular field.
In terms of rewarding investors, Mindray also spares no effort. Since its listing in 2018, the company has implemented dividends for six consecutive years, with a cumulative total dividend of 2098.1 billion yuan, far exceeding the IPO fundraising amount of 593.4 billion yuan. In the face of market volatility, the company carried out share repurchases in 2021 and 2022 respectively to safeguard the interests of shareholders. In addition, the company attaches great importance to communication with investors, and strives to improve the transparency of operation and management, and promote positive interaction between the two sides.
Mindray's action plan of "Double Improvement of Quality and Return" not only reflects the company's positive response to the first-class policy, but also demonstrates its firm determination to be "investor-oriented". Focusing on six key areas, the plan not only reflects the company's strong commitment to its core business, but also reveals its ambitions to compete in the global market.
First of all, Mindray will focus on its core business and strive to achieve a higher position in the global medical device market. The company plans to achieve its goal of entering the top 20 in the world by 2025 by strengthening investment in product research and development, accelerating the breakthrough of high-end customer groups at home and abroad, and merging and appointing global excellent targets. This strategy of both internal and external development not only promotes the company's organic growth, but also broadens the company's business scope through external mergers and acquisitions.
Second, Mindray focuses on investor returns. Since its listing, the company's performance has grown steadily and continues to give back to the capital market through high dividends. This strategy not only strengthens investor confidence in the company, but also demonstrates the company's focus on shareholder interests.
On the financial** side, we expect Mindray to continue its solid growth momentum in the coming years. It is expected that from 2023 to 2025, the company's operating income and net profit will be respectively to: 58% and. The growth rate of 74% continues to grow.
However, investing always comes with risks. Mindray also faces risks such as goodwill impairment, uncertainty in overseas market development, intensified market competition, slower than expected progress in new product development, and policy changes. Investors should fully consider these factors when making decisions.
Overall, Mindray's action plan of "Improving Quality and Return" demonstrates the company's long-term vision and firm determination. We look forward to Mindray achieving its goals in the future and delivering consistent returns to investors."
Publish a collection of dragon cards to share millions of cash